2022 Guide to Patient Support Services

Janssen

Janssen CarePath Savings Program

877-227-3728

Janssen Biotech, through Janssen CarePath, offers 1 source for patient support services focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication (Table). The Janssen Compass program, designed for patients and available at JanssenCompass.com, includes patient information about each medication, educational treatment support, financial assistance information, and tools to help patients keep up with their medication regimens.

Janssen CarePath Savings Program

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to Janssen oncology medications.

Patients may qualify for enrollment in Janssen CarePath Savings programs if they have private or commercial health insurance that will cover a portion of the cost of medication. Patients participating in federal- or state-funded programs are not eligible. Drug-specific assistance information and eligibility criteria are available by selecting the appropriate drug on our website or by calling 877-227-3728, Monday-Friday, 8 am to 8 pm ET. Enrolled patients will receive a drug-specific Janssen CarePath Savings Program Card.

Balversa Janssen CarePath Savings Program

Eligible patients with private or commercial health insurance may receive savings on out-of-pocket costs for Balversa. Depending on the patient’s health insurance plan, savings may apply toward costs for copay, coinsurance, or deductible. Eligible patients pay $5 per fill, with a $25,000 maximum program benefit per calendar year. Terms expire at the end of each calendar year and may change.

Darzalex/Darzalex Faspro and Yondelis Janssen CarePath Savings Program

Eligible patients who have been prescribed Darzalex, Darzalex Faspro, or Yondelis may be able to save on their copay, deductible, and coinsurance costs for medication. Patients enrolled in the program will receive a Janssen CarePath Savings Program Card that qualifies them to pay no more than $5 per infusion of Yondelis or Darzalex or subcutaneous injection of Darzalex Faspro, up to a $20,000 annual benefit.

Erleada Janssen CarePath Savings Program

Eligible patients may pay only $0 per month for Erleada, with an annual benefit up to $15,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Procrit Janssen CarePath

Janssen CarePath can provide information about insurance coverage, reimbursement, affordability, and access to forms for patients who are prescribed Procrit.

Rybrevant Janssen CarePath Savings Program

Eligible patients who have been prescribed Rybrevant may be able to save on their out-of-pocket medication costs. Depending on the patient’s health insurance plan, savings may apply toward copay, coinsurance, or deductible. Eligible patients will pay $5 per infusion, with a $26,000 maximum program benefit per calendar year.

Zytiga Janssen CarePath Savings Program

Eligible patients who have been prescribed Zytiga may be able to save on their copay, coinsurance, or deductible costs. Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay $10 monthly for Zytiga, up to a $12,000 annual benefit per calendar year or after 12 doses, whichever comes first.

Janssen CarePath General Resources

Access support is available online, which offers links to information on several topics, including affordability options, support for patients using government-funded healthcare programs or patients without health coverage, and the “Know Your State Interactive Tool.” It also provides a link to the Johnson & Johnson Patient Assistance Foundation, an independent, nonprofit organization that helps patients without prescription insurance coverage and without adequate financial resources to obtain their medications.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the Foundation’s patient assistance program, is available at JJPAF.org. The program is drug specific, and qualifying patients may be eligible to receive free Janssen medications for up to 12 months.

To qualify for enrollment in the Johnson & Johnson Patient Assistance Foundation, patients must:

To apply for aid from the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form. Applications, and any required documentation, may be faxed to 888-526-5168, or mailed to the address listed on the form. The patient’s medical information, including the diagnosis (and a diagnosis code) and medication-specific information (with the dosage), must be completed. For Procrit (epoetin alfa), the hemoglobin level based on the most recent laboratory results must be included.

TABLE Janssen Biotech Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Balversa (erdafitinib) tablets
Indications
Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alteration, as determined by an FDA-approved test, that has progressed during or after ≥1 lines of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Patient support programs

Drug
Darzalex (daratumumab)
Indications
Patient support programs

Drug
Darzalex Faspro (daratumumab and hyaluronidase-fihj)
Indications
Patient support programs

Drug
Erleada (apalutamide)
Indications
Treatment of metastatic and nonmetastatic castration-resistant prostate cancer
Patient support programs

Drug
Procrit (epoetin alfa)
Indications
Treatment of anemia in patients with nonmyeloid malignancies in whom anemia is due to the effect of concomitant myelosuppressive chemotherapy with a minimum of 2 additional months of planned chemotherapy
Patient support programs

Drug
Rybrevant (amivantamab-vmjw)
Indications
Adult patients with locally advanced or metastatic non–small-cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Patient support programs

Drug
Yondelis (trabectedin)
Indications
Treament of unresectable or metastatic liposarcoma or leiomyosarcoma in patients who received a prior anthracycline-containing regimen
Patient support programs

Drug
Zytiga (abiraterone acetate) tablets
Indications
Treament of metastatic castration-resistant prostate cancer, in combination with prednisone; metastatic high-risk, castration-sensitive prostate cancer, in combination with prednisone
Patient support programs

Darzalex (daratumumab) Indications

Treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant (ASCT), and in patients with relapsed or refractory multiple myeloma after ≥1 previous therapies; in combination with bortezomib, melphalan, and prednisone as first-line treatment in patients ineligible for ASCT; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with carfilzomib and dexamethasone, in patients with relapsed or refractory multiple myeloma who have received 1-3 lines of therapy; in combination with pomalidomide and dexamethasone after ≥2 previous therapies, including lenalidomide and a proteasome inhibitor (PI); as monotherapy, in patients who have received at least 3 prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent

Darzalex Faspro (daratumumab and hyaluronidase-fihj) Indications

Treatment of adults with multiple myeloma: in combination with bortezomib, melphalan, and prednisone, in newly diagnosed patients who are ineligible for autologous stem-cell transplant (ASCT); in combination with lenalidomide and dexamethasone in newly diagnosed patients swho are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received ≥1 prior therapies; in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received ≥1 prior therapies; in combination with pomalidomide and dexamethasone in patients who have received ≥1 prior therapies including lenalidomide and a proteasome inhibitor (PI); as monotherapy after ≥3 previous lines of therapy, including a PI and an immunomodulatory agent, or in patients who are double-refractory to a PI and an immunomodulatory agent

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)